• COVID-19 mRNA Vaccines and Cancer Immunotherapy

  2026-10-03

  A study by Grippin et al. links recent COVID-19 mRNA vaccination with improved outcomes during immune checkpoint inhibition, supported by retrospective patient analyses and mechanistic mouse experiments. The work suggests that an existing mRNA vaccine platform may help reshape tumor immunity, but the clinical association remains preliminary and requires prospective validation.

• BCECF for Causal pH Mapping in Efferocytosis

  2026-10-02

  BCECF enables calibrated extracellular pH mapping in macrophage efferocytosis and neuropathic pain experiments. This article shows how a ratiometric pH readout can distinguish microenvironmental effects from the AMPK/Gas6-MerTK/SOCS3 mechanism reported in ozone research.

• PDHA1 Succinylation in Cholangiocarcinoma Immunity

  2026-10-01

  The reference study identifies PDHA1 lysine 83 succinylation as a metabolic–immune switch in cholangiocarcinoma: it increases PDH activity, promotes α-ketoglutarate accumulation, and suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling. Its findings connect post-translational metabolic regulation with chemotherapy resistance and support further evaluation of succinylation-directed combination strategies.

• FLCN mRNA Rescue: From Mechanism to Translation

  2026-10-01

  Recent Birt-Hogg-Dubé research offers a compelling in vitro rationale for FLCN mRNA rescue. This thought-leadership guide connects that finding to RNA design, experimental validation, scalable T7 transcription, and the boundaries that still separate proof of concept from therapeutic translation.

• Dantrolene Sodium Salt in Calcium-Aware CRISPR

  2026-09-30

  Dantrolene sodium salt is best established as a potent, calmodulin-dependent ryanodine receptor antagonist. This thought-leadership perspective examines how controlled calcium signaling modulation could become a hypothesis-driven variable in CRISPR repair studies, while distinguishing established RyR biology from unvalidated genome-editing applications.

• Gastric Cancer Assembloids and Tumor–Stroma Biology

  2026-09-30

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal subpopulations from the same tissue. Their results show that stromal composition reshapes gene expression and drug sensitivity, providing a more informative platform for studying tumor heterogeneity, resistance, and individualized treatment responses.

• ELISA Stop Solution in Avian Vaccine Research

  2026-09-29

  ELISA Stop Solution is a critical endpoint reagent for converting enzyme-linked immunoassay chemistry into reproducible antibody data. This article connects endpoint control with the bivalent H5/H7 mRNA–LNP vaccine findings reported in SPF chickens and explains how to interpret binding-antibody results alongside neutralization and protection.

• PNU 74654: Wnt Signaling Pathway Inhibitor Workflows

  2026-09-29

  PNU 74654 provides a practical small-molecule entry point for testing Wnt/β-catenin signaling inhibition in cancer, stem cell, and differentiation models. This guide pairs product-specific handling with an evidence-aware workflow that separates pathway effects from solvent toxicity, cell-state changes, and assay artifacts.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-28

  The reference study develops patient-derived gastric cancer assembloids by combining tumor organoids with matched stromal subpopulations, producing a model that better reflects tumor heterogeneity and microenvironmental regulation. Its transcriptomic and drug-response findings show why stromal context can alter biomarker expression, progression-associated signaling, and therapeutic sensitivity.

• Niclosamide and the Translational Logic of STAT3

  2026-09-28

  Niclosamide offers translational researchers a practical way to probe STAT3-linked cancer biology while confronting a central experimental challenge: separating pathway engagement from broader cellular effects. This article connects its reported activity to assay design, evidence interpretation, and disciplined translation—without confusing preclinical findings with clinical validation.

• ALC-0159 for mRNA LNP Oncology Workflows

  2026-09-27

  ALC-0159 is a PEG-conjugated lipid excipient for building and comparing mRNA lipid nanoparticles—not a stand-alone cancer immunotherapy or evidence that a particular vaccine formulation caused clinical benefit. This guide turns recent mRNA-vaccine and checkpoint-inhibitor findings into a controlled LNP workflow, with pilot formulation conditions, assay choices, and troubleshooting priorities.

• Leucovorin Calcium in Tumor Assembloid Assays

  2026-09-26

  Use Leucovorin Calcium as a controlled folate-rescue probe to separate methotrexate sensitivity from broader tumor–stroma effects in patient-derived gastric cancer models. The workflow pairs matched organoid and assembloid assays with explicit timing, dose-ranging, and troubleshooting controls—not a presumed rescue dose.

• NIH/3T3 Cells: Practical Culture and QC Guide

  2026-09-25

  NIH/3T3 Cells (BC1017) provide a cryopreserved, adherent mouse fibroblast starting material for routine expansion and research workflows such as transfection, viral proliferation studies, and oncogene research. This guide covers recovery, culture, and quality checks; the product is for research use only and does not establish performance for a particular assay or virus.

• Palomid 529 in ESCC: Pathway Testing Workflows

  2026-09-25

  Use Palomid 529 (P529) as a pathway-level probe to test whether PI3K/Akt/mTOR activity contributes to ESCC phenotypes linked to RCN2—not as a direct RCN2 inhibitor. This workflow connects pathway readouts with cisplatin response, migration, and endothelial assays while separating established product data from experiment-specific optimization.

• Prunin Inhibits Senecavirus A via the IRES

  2026-09-24

  The study reports that prunin inhibits Senecavirus A replication in vitro and in vivo, with evidence implicating the viral internal ribosome entry site (IRES) in the effect. Its central contribution is a mechanistic link between a candidate antiviral compound and a translation-control element, although the citation information available here does not provide detailed assay conditions or effect sizes.

8719 records 1/582 page Next 12345 下5页 Last page